Stratos Investment Management LLC Grows Stake in Merck & Co., Inc. $MRK

Stratos Investment Management LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 6.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,329 shares of the company’s stock after purchasing an additional 8,090 shares during the quarter. Stratos Investment Management LLC’s holdings in Merck & Co., Inc. were worth $10,771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Chemung Canal Trust Co. lifted its position in Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after purchasing an additional 13,285 shares during the period. First Pacific Financial raised its stake in Merck & Co., Inc. by 14.7% during the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after buying an additional 6,082 shares during the last quarter. Diversified Trust Co raised its stake in Merck & Co., Inc. by 9.6% during the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after buying an additional 18,187 shares during the last quarter. Caxton Associates LLP lifted its holdings in shares of Merck & Co., Inc. by 23.3% during the 2nd quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after buying an additional 7,458 shares during the period. Finally, Amplius Wealth Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 117.4% during the 2nd quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock valued at $488,000 after buying an additional 3,329 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $117.12 on Wednesday. The stock has a 50-day simple moving average of $107.22 and a two-hundred day simple moving average of $93.75. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $122.66. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66. The firm has a market capitalization of $290.69 billion, a PE ratio of 16.09, a P/E/G ratio of 2.20 and a beta of 0.28.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 45.22% and a net margin of 28.08%.The business’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Analysts Set New Price Targets

Several analysts recently commented on the company. Guggenheim lifted their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Cantor Fitzgerald raised their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Bank of America boosted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Wells Fargo & Company upped their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Finally, Zacks Research cut shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. Eight investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $120.93.

Insiders Place Their Bets

In related news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares in the company, valued at approximately $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,176 shares of company stock worth $38,281,735 over the last ninety days. 0.09% of the stock is owned by company insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Short interest fell ~14.6% in January to ~28.7M shares (≈1.2% of float), lowering short‑pressure and reducing the odds of a short‑squeeze‑driven reversal. (Data: Jan. 30 short interest)
• Positive Sentiment: Bullish research argues Merck’s recent rally isn’t excess — analysts highlight extended Keytruda exclusivity, QLEX migration and pipeline/BD upside as durable revenue drivers. This supports longer‑term upside expectations. Merck: A Buy For 2026, But The Clock Is Still Ticking
• Positive Sentiment: Merck entered a strategic collaboration with Calla Lily Clinical Care to advance an intravaginal drug‑delivery platform (Callavid®), expanding non‑oncology device/partnered opportunities that could augment future topline or BD interest. Calla Lily Collaboration
• Neutral Sentiment: Merck reaffirmed solid fundamentals: recent quarter beat estimates, announced a $0.85 quarterly dividend (ex‑dividend March 16) and provided FY‑2026 EPS guidance. These support income/long‑term holders but may be largely priced in near term.
• Negative Sentiment: Large, high‑visibility insider sale: EVP Jennifer Zachary sold 121,573 shares (~$14.5M) at ≈$119.15 and materially reduced her stake — a prominent executive sale that can spook short‑term traders. Form 4 — Jennifer Zachary
• Negative Sentiment: Additional insider sales: CMO Chirfi Guindo sold 10,000 shares (~$1.18M) and other senior executives (including the CFO and another EVP) disclosed multi‑million dollar sales, amplifying negative sentiment from leadership selling. Form 4 — Chirfi Guindo CFO Sale Coverage
• Negative Sentiment: Some market commentary and at least one downgrade flag a near‑term balancing act — caution about valuation after a strong run and nearer‑term catalysts keeps trading volatility elevated. Balancing Act Article

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.